LeonaBio, Inc. 8-K

What Happened

• On May 7, 2026, LeonaBio, Inc. announced its financial results for the quarter ended March 31, 2026 via a press release; that press release is furnished as Exhibit 99.1 to the Form 8-K.
• The Form 8-K was signed by Mark Litton, President and CEO, and notes the company’s use of multiple channels to disclose material information.

Key Details

• Filing date: May 7, 2026; reporting quarter: ended March 31, 2026.
• Disclosure vehicle: press release furnished as Exhibit 99.1 (not “filed” for purposes of Section 18 of the Exchange Act).
• Regulation FD disclosure: LeonaBio notes it distributes material information via SEC filings, press releases, conference calls, its websites (www.leonabio.com; investors.leonabio.com), a news site, and social media (X @leonabioinc, LinkedIn, Instagram @leona.bio, Facebook).
• Signature: /s/ Mark Litton, President and Chief Executive Officer.

Why It Matters

• The company’s quarterly results are material to investors because they provide the latest information on LeonaBio’s financial and operational performance; the press release contains the numerical details investors will need (revenue, expenses, net income/loss, guidance, if provided).
• The Regulation FD statement clarifies where the company posts material updates, helping investors know where to find official disclosures.
• Because the press release is furnished (not filed), investors should review the Exhibit 99.1 press release and any subsequent SEC filings for complete financial figures and commentary.